Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Oaktree Acquisition Corp. III Life Sciences Class A ( (OACC) ).
On October 17, 2025, Oaktree Acquisition Corp. III Life Sciences appointed Dr. David A. Berry as an independent director. Dr. Berry, who brings extensive experience from his roles at Averin Capital and Flagship Pioneering, will serve on multiple committees, and his appointment aligns with Nasdaq’s listing standards for independence. Dr. Berry will not receive compensation for his role but is expected to have investment opportunities similar to other independent directors. His appointment does not involve any arrangements or transactions requiring disclosure under regulatory standards, and he has no family ties with the company’s directors or executives.
More about Oaktree Acquisition Corp. III Life Sciences Class A
Average Trading Volume: 74,783
Technical Sentiment Signal: Strong Buy
Find detailed analytics on OACC stock on TipRanks’ Stock Analysis page.